Fibrogen_US_Primary_logo_RGB_M01.jpg
FibroGen Reports First Quarter 2021 Financial Results
10 mai 2021 16h01 HE | FibroGen, Inc
Roxadustat net product revenue in China of $15.4 million, on a US GAAP basis Total roxadustat net sales in China of $43.5 million1 by FibroGen and the distribution entity jointly owned by FibroGen and...
Fibrogen_US_Primary_logo_RGB_M01.jpg
FibroGen to Report First Quarter 2021 Financial Results
03 mai 2021 07h00 HE | FibroGen, Inc
SAN FRANCISCO, May 03, 2021 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce its first quarter 2021 financial results on Monday, May 10 after the market close. FibroGen will also...
Fibrogen_US_Primary_logo_RGB_M01.jpg
FibroGen to Present at Upcoming Investor Conference
28 avr. 2021 07h00 HE | FibroGen, Inc
SAN FRANCISCO, April 28, 2021 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) announced that Enrique Conterno, Chief Executive Officer, will participate in a fireside chat at the BofA Securities...
Fibrogen_US_Primary_logo_RGB_M01.jpg
FibroGen Receives Rare Pediatric Disease Designation from the U.S. FDA for Pamrevlumab for the Treatment of Duchenne Muscular Dystrophy
15 avr. 2021 07h00 HE | FibroGen, Inc
SAN FRANCISCO, April 15, 2021 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease (RPD) Designation for...
Fibrogen_US_Primary_logo_RGB_M01.jpg
FibroGen Receives Fast Track Designation from the U.S. FDA for Pamrevlumab for the Treatment of Duchenne Muscular Dystrophy
12 avr. 2021 07h00 HE | FibroGen, Inc
SAN FRANCISCO, April 12, 2021 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for the company’s...
Fibrogen_US_Primary_logo_RGB_M01.jpg
FibroGen Announces FDA Advisory Committee to Review Roxadustat New Drug Application Tentatively Scheduled for July 15, 2021
06 avr. 2021 19h50 HE | FibroGen, Inc
SAN FRANCISCO, April 06, 2021 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) announced that the U.S. Food and Drug Administration (FDA) has informed the Company late today it has tentatively...
Fibrogen_US_Primary_logo_RGB_M01.jpg
FibroGen Provides Additional Information on Roxadustat
06 avr. 2021 16h01 HE | FibroGen, Inc
Company Continues to be Confident in the Benefit / Risk Profile of Roxadustat Company to Host Investor Call Today at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time) SAN FRANCISCO, April 06, 2021 ...
Fibrogen_US_Primary_logo_RGB_M01.jpg
FibroGen Initiates LELANTOS-2 – Second Phase 3 Clinical Study of Pamrevlumab for the Treatment of Duchenne Muscular Dystrophy
16 mars 2021 07h00 HE | FibroGen, Inc
SAN FRANCISCO, March 16, 2021 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) announced the initiation of LELANTOS-2, a Phase 3, randomized, double-blind, placebo-controlled trial of pamrevlumab...
Fibrogen_US_Primary_logo_RGB_M01.jpg
FibroGen Provides Regulatory Update on Roxadustat
01 mars 2021 16h01 HE | FibroGen, Inc
SAN FRANCISCO, March 01, 2021 (GLOBE NEWSWIRE) -- FibroGen, Inc. (Nasdaq: FGEN) and its partner, AstraZeneca (LSE/STO/Nasdaq: AZN), today announced that the Cardiovascular and Renal Drugs Advisory...
Fibrogen_US_Primary_logo_RGB_M01.jpg
FibroGen Reports Fourth Quarter and Full Year 2020 Financial Results
01 mars 2021 16h01 HE | FibroGen, Inc
• Strong Fourth Quarter China Roxadustat Net Sales of $29.2 Million and 2020 full-year Net Sales of $72.5 Million • FDA to hold Advisory Committee Meeting on Roxadustat New Drug Application SAN...